Search results for: Beta Amyloid (1 42) ELISA Kit, Human
#25424384 2015/09/19 Save this To Up
Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.Alzheimer's disease (AD) is a neurodegenerative disease that inhibits cognitive functions and has no cure. This report reviews the current diagnostic standards for AD with an emphasis on early diagnosis using the cerebrospinal fluid (CSF) biomarkers amyloid-beta, t-tau, and p-tau and fluorodeoxyglucose positron emission tomography imaging. Abnormal levels of these CSF biomarkers and decreased cerebral uptake of glucose have recently been used in the early diagnosis of AD in experimental studies. These promising biomarkers can be measured using immunoassays performed in singleplex or multiplex formats. Although presently, there are no Food and Drug Administration-approved in vitro diagnostics (IVDs) for early detection of AD, a multiplex immunoassay measuring a panel of promising AD biomarkers in CSF may be a likely IVD candidate for the clinical AD diagnostic market. Specifically, the INNO-BIA AlzBio3 immunoassay kit, performed using bead arrays on the xMAP Luminex analyzer, allows simultaneous quantification of amyloid-beta, t-tau, and p-tau biomarkers. AD biomarkers can also be screened using enzyme-linked immunosorbent assays that are offered as laboratory-developed tests.
Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Anti 3 DG imidazolone Mon rHIV gp36, soluble Antige rHIV gp41, soluble Antige Liver disease spectrum ti Lung disease spectrum tis Colon disease spectrum ti Rectum disease spectrum ( Kidney disease spectrum (
#25024322 2014/09/17 Save this To Up
Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.An increase in YKL-40 levels seems to correlate with disease severity and poor prognosis in many diseases, including several neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease (AD). Specifically, YKL-40 protein is increased in mild AD with respect to controls, both in cerebrospinal fluid (CSF) and plasma.
1243 related Products with: Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (42) ELISA K Liver disease spectrum ti Kidney disease spectrum ( Anti C Reactive Protein A YKL-39 antibody Source Ra Recombinant Sheep Interfe Native Influenza HA (A Sh Native Influenza HA (A Sh Native Influenza HA (A Sh
#23844122 2013/07/11 Save this To Up
A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.Amyloid beta (aβ) protein assembles into larger protein aggregates during the pathogenesis of Alzheimer's disease (AD) and there is increasing evidence that soluble aβ oligomers are a critical pathologic species. Diagnostic evaluations rely on the measurement of increased tau and decreased aβ42 in the cerebrospinal fluid (CSF) from AD patients and evidence for oligomeric aβ in patient CSF is conflicting. In this study, we have adapted a monoclonal single antibody sandwich ELISA assay to a Luminex platform and found that this assay can detect oligomerized aβ42 and sAPPα fragments. We evaluated oligomeric aβ reactivity in 20 patients with AD relative to 19 age matched controls and compared these values with a commercially available Alzbio3 kit that detects tau, phosphorylated tau and aβ42 on the same diagnostic platform. We found that CSF samples of patients with AD had elevated aβ oligomers compared to control subjects (p < 0.05) and the ratio of aβ oligomers to aβ42 was also significantly elevated (p < 0.0001). Further research to develop high sensitivity analytical platforms and rigorous methods of developing stable assay standards will be needed before the analysis of oligomeric aβ becomes a routine diagnostic assay for the evaluation of late onset AD patients.
2606 related Products with: A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Anti-HBeAg (HBeAb) test s Anti-HBcAg (HBcAb) test s HCV antibody test strip, H. Pylori antibody test s Integrin β1 (CD29) Antib Alkaline Phospatase (ALP) GLP 1 ELISA Kit, Rat Gluc Anti 3 DG imidazolone Mon
#23622690 2013/04/29 Save this To Up
CSF biomarker variability in the Alzheimer's Association quality control program.The cerebrospinal fluid (CSF) biomarkers amyloid beta 1-42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker measurements among and within laboratories.
1893 related Products with: CSF biomarker variability in the Alzheimer's Association quality control program.Macrophage Colony Stimula Macrophage Colony Stimula Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Leptin ELISA Kit, Rat Lep Beta Amyloid (1 40) ELISA CometAssay Electrophoresi Cell Cycle Control Phosph Thermal Shaker with cooli Colon carcinoma tissue ar Colon carcinoma tissue ar
#23302661 2013/03/21 Save this To Up
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.The aim of this study was to validate new assays for measurement of amyloid-β (Aβ) peptides in cerebrospinal fluid (CSF) and plasma specimens in clinical studies of solanezumab according to current regulatory recommendations. Four assays based on the INNOTEST® β-AMYLOID(1-42) and prototype INNOTEST β-AMYLOID(1-40) kits were developed and validated. To render these assays 'solanezumab-tolerant', excess drug was added to calibrators, quality control, and test samples via a 2-fold dilution with kit diluent. Validation parameters were evaluated by repeated testing of human CSF and EDTA-plasma pools containing solanezumab. Calibration curve correlation coefficients for the four assays were ≥0.9985. Intra- and inter-assay coefficients of variation for Aβ1-40 and Aβ1-42 were ≤13 and ≤15%, respectively for both matrices. Dilutional linearity, within and between assays, was demonstrated for both analytes in CSF and plasma at clinically relevant dilution factors. This dilution regimen was successfully applied during Phase 3 clinical sample analysis. Aβ1-40 and Aβ1-42 were stable in CSF and plasma containing solanezumab at 2-8°C and room temperature for up to 8 h and during 5 additional freeze-thaw cycles from ≤-20 and ≤-70°C. Results of parallel tests on stored clinical samples using INNOTEST methods and proprietary ELISA methods were closely correlated (r2 > 0.9), although bias in reported concentrations was observed between assays. In conclusion, the modified INNOTEST assays provided (relatively) accurate and precise quantification of Aβ1-40 and Aβ1-42 in CSF and plasma containing solanezumab according to established consensus validation criteria. The clinical experience with these assays post validation has shown them to be robust and reliable.
1158 related Products with: Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Syringe pump can be contr HBeAg test strip, Infecti Anti-HBeAg (HBeAb) test s Anti-HBcAg (HBcAb) test s HBV-5 panel test, sAg sAb HCV antibody test strip, HIV I&II test strip, Infe H. Pylori antibody test s
#22552903 2012/06/21 Save this To Up
Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid.Cerebrospinal fluid (CSF) biomarkers have been extensively utilized in the diagnosis of Alzheimer's disease (AD) and characterization of progression. One important CSF biomarker is the amyloid beta 42 (Aβ(42)) peptide, a key player in AD pathogenesis. The INNOTEST® Aβ(42) ELISA kit has been widely used but an advanced level of method development and validation has not been reported. To support a clinical trial in AD, we successfully completed a Good Laboratory Practices (GLP)-level validation of the method to establish the parameters of precision, accuracy, parallelism, selectivity, specificity, and linearity of dilution of the assay in CSF matrix, as well as CSF storage stability. Several modifications were required to optimize the assay and ensure consistent results in a clinical-trial setting. These included the use of additional calibrators, an adjusted standard curve range, a minimum required dilution (MRD) of CSF by 6-fold to avoid matrix interference and mitigation of analyte adsorption to labware by the addition of Tween-20. The optimized method displayed a quantitative range of 375-4,500 pg/mL. The inter-assay precision was ≤12.1 % CV and the inter-assay relative accuracy was ≤10.9 % absolute bias, bringing the total error of the assay to ≤23 %. The intra-assay precision of the assay at the high validation standard and below was ≤5.5 % CV; this enables sensitive detection of biomarker changes across a therapeutic regime. The INNOTEST® Aβ(42) ELISA kit, modified as reported here, may be appropriate for many applications, including regulatory agency acceptable clinical diagnosis and pharmacodynamic assessment.
1136 related Products with: Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid.FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon Interferon-a Receptor Typ Goat Anti-Human Synaptota Goat Anti-Human STK39 SPA Goat Anti-Human SPHK1, (i
#22216291 2012/01/04 Save this To Up
Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.Herpes simplex virus (HSV) reactivation has been identified as a possible risk factor for Alzheimer's disease (AD) and plasma amyloid-beta (Aβ) levels might be considered as possible biomarkers of the risk of AD. The aim of our study was to investigate the association between anti-HSV antibodies and plasma Aβ levels.
2768 related Products with: Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.Human anti-parainfluenza Goat Anti-Herpes Simplex Goat Anti-Herpes Simplex Goat Anti-Herpes Simplex Goat Anti-Herpes Simplex Mouse Anti-Herpes Simplex Recombinant Herpes Simple Recombinant Herpes Simple Recombinant Herpes Simple Mouse Anti-beta-Amyloid 1 Mouse Anti-beta-Amyloid 1 Mouse Anti-beta-Amyloid 1
#21784349 2011/07/25 Save this To Up
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.
2220 related Products with: The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.Single Donor Cerebrospina Lymphoma array, together NATtrol (Nucleic Acid Tes NATtrol CHLAMYDIA TRACHOM NATtrol CHLAMYDIA TRACHOM Syringe pump can be contr Formalin Solution (20%) Formalin Solution (20%) Formalin Solution (20%) Zinc Formalin Solution Zinc Formalin Solution MOUSE ANTI BOVINE ROTAVIR
#21047883 2011/01/06 Save this To Up
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.The clinical distinction between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) is sometimes difficult, particularly in mild cases. Although CSF markers such as amyloid β42 (Aβ42) and P-tau can distinguish between AD and normal controls, their ability to distinguish between AD and DLB is not adequate.
2074 related Products with: CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.MarkerGeneTM Fluorescent MarkerGene™ LysoLive™ Glucose Assay With the La Cultrex In Vitro Angiogen Endothelial Tube Formatio QuantiChrom™ Formaldehy QuantiChrom™ Formaldehy Formate Assay Kit MarkerGeneTM Fluorescent MarkerGeneTM Live Cell Lu MarkerGeneTM Live Dead As MarkerGeneTM Gaussia Luci
#20522869 2010/06/04 Save this To Up
Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.The clinical diagnosis of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of alpha-synuclein, beta-amyloid42 (Abeta42) and tau in the CSF of patients with DLB, Alzheimer's disease (AD) and other dementias was examined.
2152 related Products with: Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Epiandrosterone (3 beta H Syringe pump can be contr Androgen Receptor (Phosph Androgen Receptor (Phosph Macrophage Colony Stimula Macrophage Colony Stimula Androgen Receptor (Ab 650 Interferon alpha-8 antibo
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia